Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sim1 who wrote (5579)	10/24/1998 3:47:00 PM
From: Izzy	Read Replies (4) of 6136

AGPH Home Page: When I read it, I don't see any mention of AG1766, which I now realize was previously known as JE-2147, formerly known as KNI-764. This PI apparently has an excellent resistance profile and will probably be in clinical trials in 1999. It is also synergistic with Viracept. I've been unsuccessful in trying to find out if this PI will be used alone or in combination with Viracept. Does anyone know? Also, I don't find any word about S-1153 (2nd generation NNRTI from Shionogi). Has this one also been renamed with a new AGPH number? Also, what has happened with the HIV Integrase? The web site still refers to AG1343 PI (Viracept) and AG337 (Thymitaq). No wonder I'm confused. Shouldn't AGPH update its web site?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next